Search
Fluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigationalFluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. The structure of fluciclovine allows it to be uptaken by t...
Urea
go.drugbank.com/drugs/DB03904ApprovedInvestigationalA compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.
Etilefrine
go.drugbank.com/drugs/DB08985ApprovedWithdrawnIt has been used as a vasoconstrictor agent.
Canrenoic acid
go.drugbank.com/drugs/DB09015ApprovedInvestigationalWithdrawnCanrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
Dalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains ...
Flurothyl
go.drugbank.com/drugs/DB08969ApprovedWithdrawnIt was formerly used to induce convulsions as a alternative to electroshock therapy.
Interferon beta-1b
go.drugbank.com/drugs/DB00068ApprovedInvestigationalHuman interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Laronidase
go.drugbank.com/drugs/DB00090ApprovedInvestigationalThe predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalThe FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521]